Journal of Hepatology
Volume 51, Issue 1 , Pages 11-20 , July 2009

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

  • Stefan Zeuzem

      Affiliations

    • Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt a. Main, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 69 6301 6899, +49 69 6301 5122; fax: +49 69 6301 6448.
    • ,
  • Edward Gane

      Affiliations

    • Middlemore Hospital, Auckland, New Zealand
    • ,
  • Yun-Fan Liaw

      Affiliations

    • Chang Gung Memorial Hospital, Chang Gung, University College of Medicine, Taipei, Taiwan
    • ,
  • Seng G. Lim

      Affiliations

    • National University Hospital, Singapore
    • ,
  • Adrian DiBisceglie

      Affiliations

    • Saint Louis University, St. Louis, MO, USA
    • ,
  • Maria Buti

      Affiliations

    • Department of Hepatology, Hospital Universitario Vall d’Hebron and CIBER-EHD, Barcelona, Spain
    • ,
  • Anuchit Chutaputti

      Affiliations

    • Phramongkutklao Hospital, Bangkok, Thailand
    • ,
  • Jens Rasenack

      Affiliations

    • Albert Ludwigs University, Freiburg, Germany
    • ,
  • Jinlin Hou

      Affiliations

    • NanFang Hospital, First Medical University of the PLA, Guangzhou, China
    • ,
  • Christopher O’Brien

      Affiliations

    • University of Miami, Miami, FL, USA
    • ,
  • Tuan T. Nguyen

      Affiliations

    • Research and Education, Inc., San Diego, CA, USA
    • ,
  • Jidong Jia

      Affiliations

    • Capital Medical University, Beijing, China
    • ,
  • Thierry Poynard

      Affiliations

    • Groupe Hospitalier Pitie-Salpetriere, Paris, France
    • ,
  • Bruce Belanger

      Affiliations

    • Idenix Pharmaceuticals, Cambridge, MA, USA
    • ,
  • Weibin Bao

      Affiliations

    • Novartis Pharmaceuticals, East Hanover, NJ, USA
    • ,
  • Nikolai V. Naoumov

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland

References 

  1. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther. 2006;11:669–679
  2. Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido F, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986;6:167–172
  3. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  4. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL international consensus conference on hepatitis B, 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 2003;39:S3–S25
  5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  6. Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol. 2007;45:1281–1328
  7. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane EJ, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263–283
  8. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, DiBisceglie A, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology. 1988;95:1318–1325
  9. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761–763
  10. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301
  11. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102:2091–2097
  12. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129
  13. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186–194
  14. Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepatol. 1998;5:171–178
  15. van der Eijk AA, Niesters HG, Hansen BE, Heijtink RA, Janssen HLA, Schalm SW, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepatol. 2006;13:96–103
  16. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785–791
  17. Lai C-L, Gane E, Liaw Y-F, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine vs. lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  18. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Curfie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol. 2005;42:17
  19. van der Eijk AA, Hansen BE, Niesters HG, Janssen HLA, Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepatol. 2005;12:364–372
  20. Bristol Myers Squibb. Entecavir AVDAC briefing document; 2005. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/2005-4094B1_01_BristolMyersSquibb-entecavir.pdf.
  21. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban–Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–897
  22. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology; 2008 November 1 [Epub ahead of print].
  23. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–693
  24. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  25. Rustgi V, Griffith L, Westphalen T, Johnson W. A survey of hepatitis B patient demographics, disease characteristics and management practice in the United States. Gastroenterology. 2007;132:764
  26. Berg T, Benhamou Y, Calleja JL, Levrero M, Collobert C, Westphalen T, et al. A survey of chronic hepatitis B patients management practices in Europe. J. Hepatol. 2008;48:S225
  27. Fried MW, Piratvisuth T, Lau GKK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a monotherapy for HBeAg-positive CHB. Hepatology. 2008;47:428–434
  28. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309–1319
  29. Yuen MF, Fong DY, Wong DK, Yuen JCH, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007;46:1695–1703
  30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology. 2006;131:1743–1751
  31. Chan HL, Wong VW, Tse CH, Chim AML, Chan HY, Wong GLH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther. 2007;25:891–898
  32. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  33. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48:728–735
  34. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther. 2007;12:705–718
  35. Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414–1419
  36. Rapti I, Dimou E, Mitsoula P, Hadziyannis S. Adding-on vs. switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307–313
  37. Patty A, Li B, Serra I, Standring DN, Seifer M. In vitro anti-HBV activity of telbivudine/tenovofir and telbivudine/entecavir combinations. Hepatology. 2007;46:1–947[abstract 958]

☆ ClinicalTrials.gov Identifier: NCT00057265. Grant support: This study was sponsored by Idenix Pharmaceuticals, Inc. and Novartis Pharma AG. Financial disclosures: S. Zeuzem has received consulting fees from BMS, Gilead, GSK, Novartis, Roche and Schering-Plough and lecture fees from Idenix and Novartis. E. Gane has received consulting fees from Gilead, GSK and Novartis and honoraria from GSK, Idenix, Novartis and Roche. Y.-F. Liaw, Consultant for BMS, GSK, Novartis, Roche, Schering-Plough and SciClone; grant/research support from BMS, Idenix, Novartis, Roche, SciClone, and Gilead. S.-G. Lim has acted as a scientific advisor to Idenix, Novartis, and BMS and is on the speakers bureau for GSK and Schering-Plough. A. DiBisceglie: TBD. M Buti: Advisory board for Gilead, Novartis. Speaker: Gilead, Novartis, BMS, Schering-Plough. Editorial Board: Journal of Hepatology. A. Chuttaputti has no disclosures. J. Rasenack has no disclosures. J. Hou has provided scientific advice to Novartis, GSK and BMS. C. O’Brien: research grant support from Novartis, Idenix Pharmaceuticals. T.T. Nguyen: TBD. J. Jia is an investigator for the GLOBE trial and is the PI for the 015 study for Idenix and Novartis. T. Poynard: Investigator, speaker and advisory board for Idenix, Novartis, GSK, Schering, Vertex, Tibotec, BMS. B. Belanger is an employee of Idenix Pharmaceuticals. W. Bao is an employee of Novartis Pharmaceuticals. N.V. Naoumov is an employee of Novartis Pharma AG.

PII: S0168-8278(09)00063-4

doi: 10.1016/j.jhep.2008.12.019

Journal of Hepatology
Volume 51, Issue 1 , Pages 11-20 , July 2009

Article Tools

* Image Usage & Resolution